ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 136 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 4.21 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,163,830 | -42.6% | 219,177 | +3.0% | 0.00% | -100.0% |
Q2 2023 | $2,026,993 | +177395.0% | 212,696 | +105.0% | 0.00% | – |
Q1 2023 | $1,142 | -26.4% | 103,761 | -1.0% | 0.00% | -100.0% |
Q4 2022 | $1,551 | -100.0% | 104,786 | -80.3% | 0.00% | -75.0% |
Q3 2022 | $10,183,000 | +32.3% | 532,875 | +47.6% | 0.00% | +33.3% |
Q2 2022 | $7,696,000 | +115.7% | 361,143 | +66.9% | 0.00% | +200.0% |
Q1 2022 | $3,568,000 | -18.4% | 216,380 | +2.7% | 0.00% | 0.0% |
Q4 2021 | $4,371,000 | -12.1% | 210,739 | -3.9% | 0.00% | -50.0% |
Q3 2021 | $4,973,000 | -30.9% | 219,392 | -16.8% | 0.00% | 0.0% |
Q2 2021 | $7,201,000 | +11.6% | 263,846 | +18.3% | 0.00% | 0.0% |
Q1 2021 | $6,451,000 | +26.9% | 223,008 | +23.5% | 0.00% | 0.0% |
Q4 2020 | $5,082,000 | +153.7% | 180,642 | +164.2% | 0.00% | +100.0% |
Q3 2020 | $2,003,000 | +50.7% | 68,380 | +55.6% | 0.00% | 0.0% |
Q2 2020 | $1,329,000 | +14.7% | 43,955 | +13.0% | 0.00% | 0.0% |
Q1 2020 | $1,159,000 | – | 38,896 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Frazier Life Sciences Management, L.P. | 8,684,232 | $46,113,272 | 3.06% |
Pivotal bioVenture Partners Investment Advisor LLC | 1,105,309 | $5,869,191 | 2.34% |
Bain Capital Life Sciences Investors, LLC | 3,000,000 | $15,930,000 | 1.78% |
Sio Capital Management, LLC | 635,969 | $3,376,995 | 1.04% |
Rubric Capital Management LP | 5,034,530 | $26,733,354 | 1.00% |
Tejara Capital Ltd | 309,179 | $1,641,740 | 0.93% |
AlphaCentric Advisors LLC | 165,000 | $876,150 | 0.50% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 1,135,227 | $6,028,055 | 0.33% |
Orbimed Advisors | 1,914,479 | $10,165,883 | 0.22% |
Two Seas Capital LP | 164,807 | $875,125 | 0.18% |